Pharmaceutical Technology

JUNE 4, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: T-cell culturing. Immatics is a biopharmaceutical company focused on the development of T-cell immunotherapies to treat cancer.

Antibody 130

Antibody Gene Research Development 130

VirTrial

JANUARY 2, 2024

While we’re constantly publishing content on the latest science and trends in clinical research, we took a moment to reflect on what resonated with you the most in 2023. Oncology COA Measurement Strategy & Focus on PROMs Oncology will continue to be an area of concentrated focus in clinical research.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 5, 2023

Join DDW’s Megan Thomas and Reece Armstrong with sponsors Taconic for the first DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

FEBRUARY 19, 2024

Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development. antibody-drug conjugate [ADC] pipelines in some oncology settings). There is a balance, however: fast-paced change often comes with a degree of regulatory risk.

Development 59

Development Gene Therapy Drugs Antibody 59

pharmaphorum

NOVEMBER 17, 2022

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important. Healthcare professionals trust MSLs to keep them informed and up-to-date about the latest treatments, especially in fast-moving areas like oncology.

Production 113

Production Development Research 113

Drug Discovery World

NOVEMBER 10, 2023

With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer.

Drugs 52

Drugs Genome Genomics Research 52

pharmaphorum

SEPTEMBER 30, 2022

Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant improvements in survival or maintenance of a progression-free state. About CRA and the Life Sciences Practice. Lower-pricing intentionality and global possibilities.

Life Science 95

Life Science Marketing Drugs Production 95

pharmaphorum

AUGUST 5, 2022

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. 7 integrin, with three candidates in early-stage clinical development. The post Gilead snaps up MiroBio and its checkpoint agonists for $405m appeared first on.

Antibody 100

Antibody Immune Response Development Medicine 100

Pharmaceutical Technology

MAY 24, 2023

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Protein 130

Protein Antibody Medicine Development 130

Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Trials 52

Trials Development Genetic Analysis Drugs 52

pharmaphorum

JANUARY 13, 2023

Sanofi Ventures invests in innovators working in areas including immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science. The team partners across all stages of the private company lifecycle, from Seed to Series B and beyond.

Gene Therapy 52

Gene Therapy Business Development Gene Vaccination 52

Pharmaceutical Technology

MAY 15, 2023

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Antibody 130

Antibody DNA Genome Genomics 130

XTalks

MARCH 22, 2021

As a growing number of pharmaceutical companies set their sights on stepping into the burgeoning oncology space, major moves continue to be made with key cancer biotech acquisitions. s acquisition of molecular oncology leader Biotheranostics Inc. s acquisition of molecular oncology leader Biotheranostics Inc. billion by 2026.

Life Science 110

Life Science Development Marketing Gene Expression 110

Drug Discovery World

APRIL 5, 2023

Two key regenerative medicines in late stages are beremagene geperpavec, a gene therapy by Krystal Biotech for the treatment of epidermolysis bullosa, a rare dermatological condition, and Yescarta, a gene-modified cell therapy by Gilead Sciences indicated for nodal marginal zone B-cell lymphoma.

Medicine 52

Medicine Gene Therapy Drugs Gene 52

Drug Discovery World

APRIL 21, 2023

Cell therapies are an important class of therapy in immuno-oncology. They have the power to treat in a differentiated manner the disease but face their own unique challenges in development and production.

Life Science 52

Life Science Sales Protein Production 52

Drug Discovery World

OCTOBER 18, 2022

Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example. . An international business hub.

Life Science 52

Life Science Engineer Research Clinical Trials 52

Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. A focus on the representation of diverse patient populations in clinical trials will be a very good thing for the industry, but could be challenging.

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

Drug Discovery World

MAY 5, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

Drug Discovery World

APRIL 28, 2023

In this webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing at BPS Bioscience, and Dr Hengshuo Liu, Technical Sales Specialist at ACROBiosystems.

Protein 52

Protein Life Science Sales Production 52

pharmaphorum

DECEMBER 23, 2020

It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market. Servier is paying $1.8

Marketing 98

Marketing Drugs Genetics Sales 98

The Pharma Data

MARCH 23, 2021

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Trials 52

Trials Medicine Development 52

Drug Discovery World

APRIL 21, 2023

Cell therapies are an important class of therapy in immuno-oncology. They have the power to treat in a differentiated manner the disease but face their own unique challenges in development and production.

Life Science 52

Life Science Sales Protein Production 52

The Pharma Data

MARCH 21, 2021

“We are deeply saddened by the news that José Baselga, Executive Vice President Oncology R&D, and member of our Senior Executive Team, has passed away. He led a team to accelerate other exciting new science in antibody-drug conjugates, cell therapy, epigenetics, as well as new cancer treatments. AstraZeneca.

Medicine 52

Medicine Clinical Trials Clinical Trials Clinical Development 52

The Pharma Data

FEBRUARY 21, 2022

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. In the area of cardiovascular disease, Bayer is delivering on its late-stage pipeline including recent launches of Kerendia™ (finerenone) and Verquvo™ (vericiguat). “We

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

JANUARY 17, 2023

The expectations for this therapeutic area are high, with Moderna, a leading company in the space, having a broad pipeline of potential therapies targeting oncology, regenerative therapeutics, hepatitis, and other therapeutic areas. On the last point, there are already attempts to navigate the issue. Building a base.

Vaccination 94

Vaccination Vaccine In-Vivo In-Vitro 94

Pharma Marketing Network

MARCH 2, 2022

According to Murray Aitken, IQVIA’s Senior VP and Executive Director of the IQVIA Institute for Human Data Science, “the pandemic has accelerated biopharmaceutical innovation.” 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology. IQVIA’s Report Highlights.

Drugs 52

Drugs Life Science Production Gene Therapy 52

pharmaphorum

DECEMBER 20, 2022

Cancer is the major therapeutic focus area for the pharmaceutical industry. Oncology trial starts reached historic highs in 2021, and a record 30 oncology novel active substances were launched globally the same year, according to research by IQVIA.

Scientist 96

Scientist Research Genetics Drugs 96

The Pharma Data

MAY 31, 2022

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of the American Society of Clinical Oncology (ASCO) , June 3-7 in Chicago, Ill. Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “In

Research 40

Research Medicine Engineer Genetics 40

XTalks

DECEMBER 20, 2023

In 2023, there were significant advancements and notable trends in the life sciences. These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

pharmaphorum

MARCH 10, 2022

Others working in this area include Maze Therapeutics in the US. The biotech has already developed a library of genetic modifiers that could be targeted with drug treatments, and said the cash injection will be used to expand its focus into new programmes, which in turn could lead to further industry collaborations.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

Drug Discovery World

OCTOBER 16, 2023

There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharma Marketing Network

MARCH 2, 2022

According to Murray Aitken, IQVIA’s Senior VP and Executive Director of the IQVIA Institute for Human Data Science, “the pandemic has accelerated biopharmaceutical innovation.” 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology. IQVIA’s Report Highlights.

Drugs 52

Drugs Life Science Production Gene Therapy 52

Drug Discovery World

JULY 19, 2023

Over the past 15 years, the focus of my career has been building global cross-functional teams to develop drugs that help patients in need, mostly in oncology. Where do you work, and can you tell us what you’re working on at the moment? What’s been the highlight of your career so far?

Research 52

Research Development Production Clinical Development 52

pharmaphorum

MARCH 10, 2022

Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases. We will focus especially on process efficiency to guarantee the yields required to compensate for high-cost biotech active ingredients.”.

Production 98

Production Life Science Development Gene Therapy 98

Drug Discovery World

OCTOBER 4, 2022

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. She has a Biological Sciences BSc (Hons) and a PhD in Clinical Sciences from University College London. Official comments .

Drugs 52

Drugs Life Science Development Medicine 52

The Pharma Data

APRIL 11, 2023

Bayer is advancing its oncology R&D efforts in three scientific areas that have the potential to address unmet needs in cancer patients: next-generation Immuno-Oncology, Targeted Radionuclide Therapies and Precision Molecular Oncology.

Research 40

Research Clinical Trials Clinical Trials Trials 40

The Pharma Data

MARCH 16, 2021

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Medicine 52

Medicine Development 52